Eli Lilly and Co., of Indianapolis, reported results from the phase III SPARTAN study at the Congress of the International Headache Society in Vancouver, British Columbia, showing that lasmiditan, an oral molecule for the acute treatment of migraine, demonstrated statistically significant improvements vs. placebo.